7月11日,海翔药业(002099)发布公告,近期公司与中信证券进行了投资者关系活动,主要讨论了公司的原料药和CMO/CDMO业务发展情况。公告中提到,培南产品价格在经历了持续下跌后,今年二季度有所恢复,市场对其价格回暖持乐观态度。同时,公司与多家培南原研药企开展合作,确保了培南板块的持续增量。在CMO/CDMO业务方面,公司与战略客户的合作订单同比增长,且新项目正准备进入验证批发阶段。此外,公司...
Source Link7月11日,海翔药业(002099)发布公告,近期公司与中信证券进行了投资者关系活动,主要讨论了公司的原料药和CMO/CDMO业务发展情况。公告中提到,培南产品价格在经历了持续下跌后,今年二季度有所恢复,市场对其价格回暖持乐观态度。同时,公司与多家培南原研药企开展合作,确保了培南板块的持续增量。在CMO/CDMO业务方面,公司与战略客户的合作订单同比增长,且新项目正准备进入验证批发阶段。此外,公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.